» Articles » PMID: 33582171

Tackling Cancer Cell Dormancy: Insights from Immune Models, and Transplantation

Overview
Specialty Oncology
Date 2021 Feb 14
PMID 33582171
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Disseminated non-dividing (dormant) cancer cells as well as those in equilibrium with the immune response remain the major challenge for successful treatment of cancer. The equilibrium between disseminated dormant cancer cells and the immune system is reminiscent of states that can occur during infection or allogeneic tissue and cell transplantation. We discuss here the major competing models of how the immune system achieves a self nonself discrimination (pathogen/danger patterns, quorum, and coinhibition/tuning models), and suggest that taking advantage of a combination of the proposed mechanisms in each model may lead to increased efficacy in tackling cancer cell dormancy.

Citing Articles

Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence.

Tufail M, Jiang C, Li N Mil Med Res. 2025; 12(1):7.

PMID: 39934876 PMC: 11812268. DOI: 10.1186/s40779-025-00595-2.


Molecular Determinants for Photodynamic Therapy Resistance and Improved Photosensitizer Delivery in Glioma.

Aebisher D, Woznicki P, Czarnecka-Czapczynska M, Dynarowicz K, Szliszka E, Kawczyk-Krupka A Int J Mol Sci. 2024; 25(16).

PMID: 39201395 PMC: 11354549. DOI: 10.3390/ijms25168708.


The senescence journey in cancer immunoediting.

Zingoni A, Antonangeli F, Sozzani S, Santoni A, Cippitelli M, Soriani A Mol Cancer. 2024; 23(1):68.

PMID: 38561826 PMC: 10983694. DOI: 10.1186/s12943-024-01973-5.


Mitophagy-Mediated Tumor Dormancy Protects Cancer Cells from Chemotherapy.

Sun Y, Chen Y, Liu Z, Wang J, Bai J, Du R Biomedicines. 2024; 12(2).

PMID: 38397907 PMC: 10886527. DOI: 10.3390/biomedicines12020305.


Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study.

Liu W, Ma F, Sun B, Liu Y, Tang H, Luo J Front Immunol. 2022; 12:756872.

PMID: 34975845 PMC: 8716485. DOI: 10.3389/fimmu.2021.756872.